![](/img/cover-not-exists.png)
Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan⁎⁎The views expressed in this article are those of the author and do not necessarily reflect the official views of Ministry of Health, Labor, and Welfare, or the Pharmaceuticals Medical Devices Agency of Japan.
Otsubo, YasutoLanguage:
english
Journal:
Clinical Therapeutics
DOI:
10.1016/j.clinthera.2015.04.010
Date:
May, 2015
File:
PDF, 171 KB
english, 2015